-
The marketing application for antidote medicinal charcoal suspension particles for children is planned to be included in the priority review
Time of Update: 2022-01-03
The medicinal charcoal suspension particles declared this time are the first varieties to declare this dosage form in China .
-
Insulin centralized procurement: some products are less than 20 yuan per branch, and the gap between Tonghua Dongbao and Tonghua is widening?
Time of Update: 2022-01-03
Among domestic companies, Ganli Pharmaceutical, United Laboratories, Tonghua Dongbao, Hefei Tianmai, Jiangsu Wanbang, Dongyang Sunshine, and Hisun Pharmaceutical won the bids for 6, 6, 5, 3, 2, 2, and 1 products respectively .
-
DPP1 inhibitor ill-fated, AstraZeneca brensocatib changes hands and takes a turn for the better
Time of Update: 2022-01-03
In September 2020, Insmed announced that the Phase 2 clinical study WILLOW of brensocatib in the treatment of non-cystic fibrosis bronchiectasis (NCFBE) reached the primary endpoint .
-
The quantity of Chinese medicinal materials is small and the price is high. What impact will it have on Chinese medicine companies?
Time of Update: 2022-01-03
In fact, compared with pharmaceutical companies, the industry believes that the increase in the price of Chinese medicinal materials will have a greater impact on planting companies .
-
From structure to clinical muscarinic M1 receptor agonist may become a new treatment for AD
Time of Update: 2022-01-03
The researchers detailed a new molecular drug they designed to selectively target specific receptor proteins in the brain, and demonstrated the potential of this method in the development of new drugs to improve the cognitive function of patients with Alzheimer's disease .
-
Announcement of the results of the national centralized drug procurement (special insulin project)
Time of Update: 2022-01-03
Attachment 1 : Selection result table of national centralized drug procurement (insulin special item) Attachment 2: List of products to be supplied after the selection in the national centralized drug procurement (insulin special item) On the afternoon of November 30th, Shanghai Sunshine Pharmaceutical Purchasing Network issued an announcement stating that in accordance with the "National Drug Centralized Purchasing Document (Insulin Special) (GY-YD2021-3)", the Joint Purchasing Office has carried out special centralized purchasing of insulin.
-
2 billion large varieties!
Time of Update: 2022-01-03
On November 29, Buchang Pharmaceuticals announced that its wholly-owned subsidiary Shandong Danhong's parecoxib sodium for injection was approved for listing .
Parecoxib sodium for injection is a selective COX-2 inhibitor, and its terminal sales in China's public medical institutions will exceed 2 billion yuan in 2020 .
-
A large number of pharmaceutical companies announced layoffs. What are the reasons?
Time of Update: 2022-01-03
In addition to November, many pharmaceutical companies announced layoffs in October .
According to Fierce pharma on October 13, 2021, Ardelyx plans to lay off 65% of its employees because the FDA will not provide clear information to biopharmaceutical companies on the prospects of its chronic kidney disease drugs .
-
Tianyan Pharmaceutical's anti-CTLA-4 antibody was approved for clinical use in the U.S.
Time of Update: 2022-01-03
On November 30, Tianyan Pharmaceuticals announced that the US FDA has approved its Phase 1b/2 clinical trial application for the combination therapy of its anti-CTLA-4 monoclonal antibody (mAb) ADG116 and anti-PD-1 antibody pembrolizumab .
-
Pharmaceutical companies such as Xianju Pharmaceutical and Minova accept surveys from more than 10 institutions
Time of Update: 2022-01-03
In addition, in answering the company’s mid- and long-term strategic positioning and future development layout, Xianju Pharmaceutical said that the company has an integrated industrial chain of APIs and preparations, a complete manufacturing system (Chinese factories and Italian factories), and sales both domestic and foreign.
-
Holding a group to resist the cold winter, a wave of "cooperation" between domestic pharmaceutical companies has begun
Time of Update: 2022-01-03
For example, on November 22, Connoa announced that it has exclusively authorized the innovative drug CM326 (a recombinant humanized monoclonal antibody against TSLP) with CSPC in moderate to severe asthma and chronic obstructive pulmonary disease (COPD) and other respiratory diseases A formal agreement was signed for development and commercialization .
-
The homogeneity of domestic innovative drugs is serious, and the "quality" needs to be accelerated
Time of Update: 2022-01-03
In addition to making competitive, differentiated, and valuable products, the industry believes that domestic innovative companies should also set their sights on overseas markets .
-
What are the symptoms of being infected with Omi Keron strain?
Time of Update: 2022-01-03
The WHO said on the 28th that it is still unclear whether the Omi Kiron strain will cause more serious diseases, and it is cooperating with experts to understand the impact of the Omi Kiron strain on current epidemic prevention measures, including vaccination .
-
The third series of pharmaceutical excipients-functional indicators of pharmaceutical excipients (FRCs)
Time of Update: 2022-01-03
(1) Critical micelle concentration (CMC)It is an important indicator for surfactants to perform their functions.
-
The first KRAS inhibitor license out!
Time of Update: 2022-01-03
According to the terms of the agreement, Jiyu Medicine will exclusively license the development, production and commercialization rights of the KRAS inhibitor JMKX1899 with independent intellectual property rights outside the Greater China Region to Huya, and the relevant rights and interests of JMKX1899 in the Greater China Region will remain with Jimin Trust.
-
API companies have expanded production, or accelerated the innovation and upgrade of the pharmaceutical machinery industry
Time of Update: 2022-01-02
API companies have expanded production, forcing the pharmaceutical machinery industry to accelerate innovation and upgrading (Source: Pharmaceutical Network) Many API projects over 100 million yuan have started construction.
-
Nuggets overweight/obesity drug market GLP-1 receptor agonists do their part
Time of Update: 2022-01-02
At present, a variety of GLP-1 receptor agonists in China have been developed for overweight/obesity.
The drug is a long-acting molecule that is injected once a week and has been shown to effectively control blood sugar and reduce the weight of subjects in early clinical trials .
-
The development of the domestic pharmaceutical outsourcing industry continues to be prosperous, and a large number of companies will benefit
Time of Update: 2022-01-02
In recent years, with the growth of labor and environmental protection costs in overseas markets, global innovative drug outsourcing services are shifting to emerging Asian markets such as China; and the industrial chain of new drug R&D and production has continued to become more complex and refined, resulting in increased costs and increased R&D difficulties.
-
Two specifications of Jianmin Biantong Capsules are cancelled
Time of Update: 2022-01-02
Recently, the Shanxi Provincial Pharmaceutical Equipment Centralized Bidding and Procurement Center issued a notice on publicizing Jianmin Pharmaceutical Group Co.
bid for two drug product regulations to apply for cancellation of the platform's online procurement qualification.
-
Over 700 million yuan in antibiotic varieties, ushering in another over-rated pharmaceutical company!
Time of Update: 2022-01-02
On December 1, Huluwa Pharmaceuticals issued an announcement stating that the company had recently received the "Drug Supplementary Application Approval Notice" on "Azithromycin for Injection" approved and issued by the State Food and Drug Administration.
